Cargando…
Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438013/ https://www.ncbi.nlm.nih.gov/pubmed/34518582 http://dx.doi.org/10.1038/s41598-021-97404-2 |
_version_ | 1783752277901705216 |
---|---|
author | Zakošek Pipan, Maja Prpar Mihevc, Sonja Štrbenc, Malan Košak, Urban German Ilić, Ilija Trontelj, Jurij Žakelj, Simon Gobec, Stanislav Pavlin, Darja Majdič, Gregor |
author_facet | Zakošek Pipan, Maja Prpar Mihevc, Sonja Štrbenc, Malan Košak, Urban German Ilić, Ilija Trontelj, Jurij Žakelj, Simon Gobec, Stanislav Pavlin, Darja Majdič, Gregor |
author_sort | Zakošek Pipan, Maja |
collection | PubMed |
description | Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this. |
format | Online Article Text |
id | pubmed-8438013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84380132021-09-15 Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor Zakošek Pipan, Maja Prpar Mihevc, Sonja Štrbenc, Malan Košak, Urban German Ilić, Ilija Trontelj, Jurij Žakelj, Simon Gobec, Stanislav Pavlin, Darja Majdič, Gregor Sci Rep Article Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this. Nature Publishing Group UK 2021-09-13 /pmc/articles/PMC8438013/ /pubmed/34518582 http://dx.doi.org/10.1038/s41598-021-97404-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zakošek Pipan, Maja Prpar Mihevc, Sonja Štrbenc, Malan Košak, Urban German Ilić, Ilija Trontelj, Jurij Žakelj, Simon Gobec, Stanislav Pavlin, Darja Majdič, Gregor Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor |
title | Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor |
title_full | Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor |
title_fullStr | Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor |
title_full_unstemmed | Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor |
title_short | Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor |
title_sort | treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438013/ https://www.ncbi.nlm.nih.gov/pubmed/34518582 http://dx.doi.org/10.1038/s41598-021-97404-2 |
work_keys_str_mv | AT zakosekpipanmaja treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT prparmihevcsonja treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT strbencmalan treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT kosakurban treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT germanilicilija treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT tronteljjurij treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT zakeljsimon treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT gobecstanislav treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT pavlindarja treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT majdicgregor treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor |